Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects

P Lopez-Legarrea, R de la Iglesia, A B Crujeiras, M Pardo, F F Casanueva, M A Zulet, J A Martinez, P Lopez-Legarrea, R de la Iglesia, A B Crujeiras, M Pardo, F F Casanueva, M A Zulet, J A Martinez

Abstract

Irisin is assumed to be a relevant link between muscle and weight maintenance as well as to mediate exercise benefits on health. The aim of this study was to assess the possible associations between irisin levels and glucose homeostasis in obese subjects with metabolic syndrome (MetS) following an energy-restricted treatment. Ninety-six adults with excessive body weight and MetS features underwent a hypocaloric dietary pattern for 8 weeks, within the RESMENA randomized controlled trial (www.clinicaltrials.gov; NCT01087086). After the intervention, dietary restriction significantly reduced body weight and evidenced a dietary-induced decrease in circulating levels of irisin in parallel with improvements on glucose homeostasis markers. Interestingly, participants with higher irisin values at baseline (above the median) showed a greater reduction on glucose (P=0.022) and insulin (P=0.021) concentrations as well as on the homeostasis model assessment index (P=0.008) and triglycerides (P=0.006) after the dietary intervention, compared with those presenting low-irisin baseline values (below the median). Interestingly, a positive correlation between irisin and carbohydrate intake was found at the end of the experimental period. In conclusion, irisin appears to be involved in glucose metabolism regulation after a dietary-induced weight loss.

Figures

Figure 1
Figure 1
Irisin changes from baseline (week 0) to the end (week 8) of the intervention (a); changes in glucose, insulin, HOMA index and triglycerides, depending on irisin baseline levels after the intervention of 8 weeks duration (b); and irisin correlation with carbohydrate intake (cereals, pulse, fruits and vegetables) at the endpoint of the intervention (c).

References

    1. Straughen JK, Trudeau S, Misra VK. Changes in adipose tissue distribution during pregnancy in overweight and obese compared with normal weight women. Nutr Diabetes. 2013;3:e84.
    1. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;481:463–468.
    1. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity—Correlation with body mass index. Peptides. 2013;39:125–130.
    1. Liu JJ, Wong MD, Toy WC, Tan CS, Liu S, Ng XW, et al. Lower circulating irisin is associated with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:365–369.
    1. Roberts MD, Bayless DS, Company JM, Jenkins NT, Padilla J, Childs TE, et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats. Metabolism. 2013;62:1052–1056.
    1. Roca-Rivada A, Castelao C, Senin L, Landrove M, Baltar J, Crujeiras A, et al. FNDC5/irisin is not only a myokine but also an adipokine. PLoS One. 2013;8:e60563.
    1. Moreno-Navarrete JM, Ortega F, Serrano M, Guerra E, Pardo G, Tinahones F, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013;98:E769–E778.
    1. Huh JY, Panagiotou G, Mougios V, Brinkoetter M, Vamvini MT, Schneider BE, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012;61:1725–1738.
    1. Lopez-Legarrea P, de la Iglesia R, Abete I, Bondia-Pons I, Navas-Carretero S, Forga L, et al. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese with metabolic syndrome symptoms: the RESMENA randomized controlled trial. Nutr Metab (Lond) 2013;10:22.
    1. Lopez-Legarrea P, De la Iglesia R, Abete I, Navas-Carretero S, Martinez JA, Zulet MA.The protein type within a hypocaloric diet affects obesity-related inflammation: the RESMENA project Nutrition 2013. doi:10.1016/j.nut.2013.09.009
    1. Crujeiras AB, Goyenechea E, Abete I, Lage M, Carreira MC, Martinez JA, et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab. 2010;95:5037–5044.
    1. Castillo-Quan JI. From white to brown fat through the PGC-1alpha-dependent myokine irisin: implications for diabetes and obesity. Dis Model Mech. 2012;5:293–295.
    1. Kelly DP. Medicine. Irisin, light my fire. Science. 2012;336:42–43.
    1. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. Irisin: a new potential hormonal target for the treatment of obesity and type 2 diabetes. J Diabetes. 2012;4:196.
    1. Bostrom PA, Fernandez-Real JM. Metabolism: irisin, the metabolic syndrome and follistatin in humans. Nat Rev Endocrinol. 2014;10:11–12.
    1. Katcher HI, Legro RS, Kunselman AR, Gillies PJ, Demers LM, Bagshaw DM, et al. The effects of a whole grain-enriched hypocaloric diet on cardiovascular disease risk factors in men and women with metabolic syndrome. Am J Clin Nutr. 2008;87:79–90.
    1. Al-Daghri N, Alkharfy K, Rahman S, Amer O, Vinodson B, Sabico S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects Eur J Clin Invest 2013. e-pub ahead of print 5 November 2013; doi:10.1111/eci.12196
    1. Karpe F, Dickmann JR, Frayn KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes. 2011;60:2441–2449.
    1. Swick AG, Orena S, O'Connor A. Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass. Metabolism. 2013;62:1070–1073.
    1. Zhang HJ, Zhang XF, Ma ZM, Pan LL, Chen Z, Han HW, et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. J Hepatol. 2013;59:557–562.
    1. Park KH, Zaichenko L, Brinkoetter M, Thakkar B, Sahin-Efe A, Joung KE, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013;98:4899–4907.
    1. Choi YK, Kim MK, Bae KH, Seo HA, Jeong JY, Lee WK, et al. Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract. 2013;100:96–101.
    1. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011;378:169–181.
    1. Makris A, Darcey VL, Rosenbaum DL, Komaroff E, Vander Veur SS, Collins BN, et al. Similar effects on cognitive performance during high- and low-carbohydrate obesity treatment. Nutr Diabetes. 2013;3:e89.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner